Page last updated: 2024-09-04

birb 796 and Colitis, Granulomatous

birb 796 has been researched along with Colitis, Granulomatous in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Bingham, K; Bunton, D; Carrieri, AP; Gardiner, LJ; Macluskie, G; McNeil, M; Pyzer-Knapp, EO	1
Bernstein, CN; Colombel, JF; D'Haens, G; Feagan, B; Geboes, K; Golovenko, O; Isakov, V; Ludwig, D; Meier, U; Schreiber, S; Steffgen, J; Winter, T; Yong, C; Yurcov, M	1

Trials

1 trial(s) available for birb 796 and Colitis, Granulomatous

Article	Year
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2006, Volume: 4, Issue:3 Topics: Administration, Oral; Adult; Crohn Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Pyrazoles; Treatment Outcome	2006

Article

Year

Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2006, Volume: 4, Issue:3

Topics: Administration, Oral; Adult; Crohn Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Pyrazoles; Treatment Outcome

2006

Other Studies

1 other study(ies) available for birb 796 and Colitis, Granulomatous

Article	Year
Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. PloS one, 2022, Volume: 17, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Drug Evaluation, Preclinical; Female; Genomics; Humans; Machine Learning; Male; Mesalamine; Middle Aged; Naphthalenes; Phenylurea Compounds; Precision Medicine; Prednisolone; Pyrazoles; Signal Transduction; Transcriptome; Tumor Necrosis Factor-alpha; Young Adult	2022

Article

Year

Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease.

PloS one, 2022, Volume: 17, Issue:2

Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Drug Evaluation, Preclinical; Female; Genomics; Humans; Machine Learning; Male; Mesalamine; Middle Aged; Naphthalenes; Phenylurea Compounds; Precision Medicine; Prednisolone; Pyrazoles; Signal Transduction; Transcriptome; Tumor Necrosis Factor-alpha; Young Adult

2022